Keros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results

Keros Therapeutics (NASDAQ:KROS) released its earnings results on Wednesday. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.37), FiscalAI reports. Keros Therapeutics had a net margin of 26.12% and a return on equity of 9.51%. The firm had revenue of $0.39 million during the quarter, compared to the consensus estimate of $3.66 million.

Keros Therapeutics Price Performance

Shares of NASDAQ KROS traded up $0.37 during mid-day trading on Wednesday, hitting $13.77. 366,062 shares of the company’s stock traded hands, compared to its average volume of 329,928. The company’s 50-day moving average is $17.98 and its two-hundred day moving average is $17.12. Keros Therapeutics has a 1 year low of $9.12 and a 1 year high of $22.55. The company has a market capitalization of $419.57 million, a P/E ratio of 8.94 and a beta of 0.87.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Brooklyn Investment Group grew its position in Keros Therapeutics by 22,733.0% during the 3rd quarter. Brooklyn Investment Group now owns 20,778 shares of the company’s stock worth $329,000 after purchasing an additional 20,687 shares during the period. Creative Planning raised its position in Keros Therapeutics by 40.2% during the second quarter. Creative Planning now owns 24,226 shares of the company’s stock worth $323,000 after acquiring an additional 6,948 shares during the period. Lazard Asset Management LLC acquired a new position in shares of Keros Therapeutics during the second quarter valued at approximately $291,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Keros Therapeutics during the third quarter worth about $287,000. Finally, VARCOV Co. purchased a new position in Keros Therapeutics during the fourth quarter worth approximately $261,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on KROS shares. Oppenheimer reiterated an “outperform” rating and set a $27.00 price target (up from $23.00) on shares of Keros Therapeutics in a report on Wednesday, November 12th. TD Cowen raised shares of Keros Therapeutics to a “hold” rating in a research note on Friday, December 19th. Wedbush raised their price target on Keros Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. Wells Fargo & Company decreased their price objective on shares of Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating for the company in a report on Tuesday, November 11th. Finally, Zacks Research cut shares of Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Five analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Keros Therapeutics currently has an average rating of “Hold” and a consensus price target of $22.29.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.